(Q34252786)

31 July 2017

title

Azacitidine in 302 patients with WHO-defined acute myeloid leukemia: results from the Austrian Azacitidine Registry of the AGMT-Study Group (English)

1 reference

World Health Organization

31 July 2017

main subject

0 references

0 references

1 reference

acute myeloid leukemia

1 reference

1

Lisa Pleyer

1 reference

31 July 2017

20

Richard Greil

1 reference

31 July 2017

5

Reinhard Stauder

1 reference

31 July 2017

Sonja Burgstaller

2

1 reference

31 July 2017

Michael Girschikofsky

3

1 reference

31 July 2017

Werner Linkesch

4

1 reference

31 July 2017

Michael Pfeilstocker

6

1 reference

31 July 2017

Martin Schreder

7

1 reference

31 July 2017

Christoph Tinchon

8

1 reference

31 July 2017

Thamer Sliwa

9

1 reference

31 July 2017

Alois Lang

10

1 reference

31 July 2017

Wolfgang R Sperr

11

1 reference

31 July 2017

Peter Krippl

12

1 reference

31 July 2017

Dietmar Geissler

13

1 reference

31 July 2017

Daniela Voskova

14

1 reference

31 July 2017

Konstantin Schlick

15

1 reference

31 July 2017

Josef Thaler

16

1 reference

31 July 2017

Sigrid Machherndl-Spandl

17

1 reference

31 July 2017

Georg Theiler

18

1 reference

31 July 2017

Otto Eckmüllner

19

1 reference

31 July 2017

publication date

21 June 2014

1 reference

31 July 2017

1 reference

31 July 2017

volume

93

1 reference

31 July 2017

issue

11

1 reference

31 July 2017

page(s)

1825-1838

1 reference

Creative Commons Attribution 4.0 International

31 July 2017

copyright license

start time

21 June 2014

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

0 references

cites work

Azacitidine in patients with WHO-defined AML - results of 155 patients from the Austrian Azacitidine Registry of the AGMT-Study Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4176957

Transfusion independence and survival in patients with acute myeloid leukemia treated with 5-azacytidine

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4176957

Azacitidine in patients with acute myeloid leukemia medically unfit for or resistant to chemotherapy: a multicenter phase I/II study

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4176957

Acute myeloid leukemia with monosomal karyotype at the far end of the unfavorable prognostic spectrum

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4176957

Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4176957

Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4176957

Acute myeloid leukemia in the elderly

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4176957

Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B.

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4176957

Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4176957

Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4176957

The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4176957

International scoring system for evaluating prognosis in myelodysplastic syndromes

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4176957

Prognostic factors in acute myeloid leukaemia

28 July 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-014-2126-9

The difficult problem of acute myeloid leukemia in the older adult

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-014-2126-9

Treatment of acute myelogenous leukemia with outpatient azacitidine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-014-2126-9

Treatment of progression of Philadelphia-negative myeloproliferative neoplasms to myelodysplastic syndrome or acute myeloid leukemia by azacitidine: a report on 54 cases on the behalf of the Groupe Francophone des Myelodysplasies (GFM).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-014-2126-9

Platelet doubling after the first azacitidine cycle is a promising predictor for response in myelodysplastic syndromes (MDS), chronic myelomonocytic leukaemia (CMML) and acute myeloid leukaemia (AML) patients in the Dutch azacitidine compassionate n

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-014-2126-9

Azacitidine in CMML: matched-pair analyses of daily-life patients reveal modest effects on clinical course and survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-014-2126-9

Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-014-2126-9

Monosomal karyotype in acute myeloid leukemia: a better indicator of poor prognosis than a complex karyotype

21 January 2018

1 reference

12 December 2020

Monosomal karyotype in adult acute myeloid leukemia: prognostic impact and outcome after different treatment strategies

1 reference

12 December 2020

Azacitidine for the treatment of patients with acute myeloid leukemia: report of 82 patients enrolled in an Italian Compassionate Program

1 reference

12 December 2020

Azacitidine results in comparable outcome in newly diagnosed AML patients with more or less than 30% bone marrow blasts

1 reference

12 December 2020

Azacitidine in untreated acute myeloid leukemia: a report on 149 patients

1 reference

12 December 2020

10.1007/S00277-014-2126-9

Identifiers

DOI

1 reference

31 July 2017

1 reference

31 July 2017

1 reference